Incyte yanks EU application for PD-1 drug, citing inability to answer regulators' 'major concerns'
Hoping to wedge its way into a crowded PD-(L)1 field, Incyte faced a huge setback when the FDA sent back its application for an initial indication earlier this year. Now, the drugmaker is giving up hope in Europe as well.
Incyte has withdrawn its EU application for PD-1 drug Zynyz, or retifanlimab, after saying it couldn’t adequately address the CHMP’s questions over survival data underpinning its market hopes in squamous cell carcinoma of the anal cavity, the EMA revealed.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.